About 400 reports

Sandoz is seeking approval for all indications included in the label of the reference product which is used to treat a range of autoimmune diseases including rheumatoid arthritis and psoriasis.

  • Autoimmune Disease
  • Biosimilar
  • United States
  • Company Operations
  • Coherus BioSciences, Inc.
  • different mechanism of action and wherein the composition gives rise to a synergistic effect on the IDO levels.
  • HANSA MEDICAL AB

Kidney Transplant Rejection - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H1 2018, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape. Kidney...

  • Autoimmune Disease
  • Healthcare
  • Therapy
  • United States
  • Product Initiative
  • ANCA VASCULITIS - PIPELINE BY KINETA, INC., H1 2016
  • DALAZATIDE - DRUG PROFILE

AARV is a serious autoimmune disease causing inflammation of the smaller blood vessels.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • 7.2 AUTOIMMUNE DISEASES
  • EUROPE: OTHER AUTOIMMUNE DISEASES MARKET SIZE, BY COUNTRY, 2013-2020 ($MILLION)

The European injectable drug delivery market is expected to reach $207.3 billion by 2020 from $114.7 billion in 2015, growing at a CAGR of 12.6% from 2015 to 2020. The market is categorized on the basis of type, therapeutic application, usage pattern, mode of administration, end user, and region. The therapeutic application market is further...

  • Autoimmune Disease
  • Europe
  • World
  • Market Size
  • Pfizer Inc.
  • Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) - Companies Involved in Therapeutics Development
  • Nov 10, 2010: ChemoCentryx Presents Positive Phase I Results For CCX168 At Annual American College Of Rheumatology Meeting

AARV is a serious autoimmune disease causing inflammation of the smaller blood vessels.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • GlaxoSmithKline plc
  • R&D Progress Research and Development Brief

Palatin Technologies is developing PL-## for the treatment of autoimmune uveitis, Inflammatory bowel disease and nephritis.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Clinuvel Pharmaceuticals Limited

A team of Weizmann Institute scientists has turned the tables on an autoimmune disease.

  • Autoimmune Disease
  • Cardiovascular Disease
  • World
  • Product Initiative
  • Gilead Sciences, Inc.
  • Pipeline by Mitsubishi Tanabe Pharma Corp, H1 2018

The company develops ethical drugs for autoimmune disease, diabetes and kidney diseases, central nervous system (CNS) diseases and others, and it also develops vaccines.

  • Autoimmune Disease
  • Leukemia
  • World
  • Product Initiative
  • Forma Publishing Group
  • ATLANTIC BIO SCI LLC
  • ABS-11 - DRUG PROFILE

Crohn’s Disease (Regional Enteritis) - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Crohn’s Disease (Regional Enteritis) - Pipeline Review, H2 2017, provides an overview of the Crohn’s Disease (Regional Enteritis) (Gastrointestinal) pipeline landscape. Crohn’s...

  • Arthritis
  • Autoimmune Disease
  • United States
  • Company
  • Product Initiative

CLINICAL TRIALS BY END POINT STATUS INTERSTITIAL LUNG DISEASES (DIFFUSE PARENCHYMAL LUNG DISEASE) THERAPEUTICS CLINICAL TRIALS, GLOBAL, BY END POINT STATUS, 2017* INTERSTITIAL LUNG DISEASES (DIFFUSE PARENCHYMAL LUNG DISEASE) THERAPEUTICS CLINICAL TRIALS, GLOBAL, B

  • Autoimmune Disease
  • Drug Discovery And Development
  • Respiratory Disease
  • World
  • Product Initiative

RhuDex is a modifying agent for the oral treatment of autoimmune diseases.

  • Autoimmune Disease
  • Japan
  • Company
  • Deals & Alliance
  • Dr. Falk Pharma GmbH
  • GUILLAIN-BARRE SYNDROME - PIPELINE BY COMPLEMENT PHARMA BV, H1 2018
  • GUILLAIN-BARRE SYNDROME - PIPELINE BY HANSA MEDICAL AB, H1 2018

Guillain-Barre Syndrome - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Guillain-Barre Syndrome - Pipeline Review, H1 2018, provides an overview of the Guillain-Barre Syndrome (Central Nervous System) pipeline landscape. Guillain-Barre...

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Akari Therapeutics, Plc
  • PLAQUE PSORIASIS (PSORIASIS VULGARIS) - PIPELINE BY LYCERA CORP., H2 2016
  • PLAQUE PSORIASIS (PSORIASIS VULGARIS) - PIPELINE BY CALCIMEDICA, INC., H2 2016

Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Plaque Psoriasis (Psoriasis Vulgaris) - Pipeline Review, H2 2016, provides an overview of the Plaque Psoriasis (Psoriasis Vulgaris) (Immunology) pipeline landscape. Plaque...

  • Autoimmune Disease
  • Biotech
  • United States
  • Company
  • Company Operations
  • JUN 24, 2013: ANTHERA PHARMA INITIATES BRIGHT-SC PHASE II CLINICAL STUDY IN IGA NEPHROPATHY WITH BLISIBIMOD
  • BLISIBIMOD - DRUG PROFILE

WHEN BLYS IS OVER-EXPRESSED, IT LEADS TO THE DEVELOPMENT OF AUTOIMMUNE DISEASES.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Musculoskeletal Disorder
  • World
  • Product Initiative
  • Granulomatosis with Polyangiitis (Wegener Polyangiitis) - Product Development Milestones
  • GRANULOMATOSIS WITH POLYANGIITIS (WEGENER POLYANGIITIS) - PIPELINE BY CELLTRION INC, H1 2018

C##AR IS A COMPONENT OF THE BODY' S COMPLEMENT SYSTEM AND A POTENT DRIVER OF THE INFLAMMATORY RESPONSE ASSOCIATED WITH AUTOIMMUNE DISEASES.

  • Autoimmune Disease
  • Hospital
  • United States
  • World
  • Product Initiative
  • BULLOUS PEMPHIGOID - PIPELINE BY IMMUNGENETICS AG, H2 2017
  • IMMUNGENETICS AG

IND application for the treatment of BP, a rare autoimmune skin disease known to have increased eotaxin-## levels in serum and blister fluids.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • BULLOUS PEMPHIGOID - PIPELINE BY IMMUNGENETICS AG, H1 2018
  • BULLOUS PEMPHIGOID - PIPELINE BY TXCELL SA, H1 2018

IND application for the treatment of BP, a rare autoimmune skin disease known to have increased eotaxin-## levels in serum and blister fluids.

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • United States
  • Product Initiative
  • Clinical Trial Profile Snapshots

Rtx-BD Trial (Rituximab of Intractable Autoimmune Bullous Disease Trial) ## Exploratory Research on Effectiveness and Safety of Rituximab Treatment Including Maintenance Administration for Steroid Intractable Autoimmune Bullous Diseases of the Skin (Rtx-BD Trial ##)

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • World
  • Product Initiative
  • KADMON AND OTHERS ON THE ROCK2 SIGNALING PATHWAY AND SUPPORTS ROCK2 AS A THERAPEUTIC TARGET IN AUTOIMMUNITY.
  • SMALL MOLECULES TO INHIBIT PORCUPINE FOR IMMUNOLOGY, RESPIRATORY, GASTROINTESTINAL AND METABOLIC DISORDERS - DRUG PROFILE

The company develops products for fibrosis, anemia, autoimmune diseases, inflammation, and nephropathies.

  • Autoimmune Disease
  • Research And Development
  • United States
  • Product Initiative
  • ProMetic Life Sciences Inc.
  • R&D Progress
  • MEDI-7734 - DRUG PROFILE

Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2018 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Systemic Sclerosis (Scleroderma) - Pipeline Review, H1 2018, provides an overview of the Systemic Sclerosis (Scleroderma) (Immunology) pipeline landscape. Scleroderma...

  • Autoimmune Disease
  • Dermatological Condition
  • Lymphoma
  • Musculoskeletal Disorder
  • Seattle Genetics, Inc.
  • Official Title
  • Clinical Trial Profile Snapshots

Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016 Summary GlobalData's clinical trial report, “Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis (ANCA Vasculitis) Global Clinical Trials Review, H2, 2016" provides an overview of Anti-Neutrophil...

  • Autoimmune Disease
  • Monoclonal Antibody
  • Therapy
  • World
  • Product Initiative
  • HuABC-2 - Drug Profile

The company develops drugs for treating inflammation, autoimmune, cancer and neurodegenerative diseases.

  • Autoimmune Disease
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • VASCULITIS - PIPELINE BY EPIRUS BIOPHARMACEUTICALS, INC., H1 2016
  • VASCULITIS - PIPELINE BY CHEMOCENTRYX, INC., H1 2016

Its pipeline product portfolio includes BOW##, BOW##, BOW## and BOW## for the treatment of autoimmune diseases.

  • Autoimmune Disease
  • Monoclonal Antibody
  • United States
  • Product Initiative
  • AnGes MG, Inc.
  • HANSA MEDICAL AB
  • KIDNEY TRANSPLANT REJECTION - PIPELINE BY JOHNSON & JOHNSON, H2 2017

Kidney Transplant Rejection - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2017, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape. Kidney transplantation...

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.
  • Pipeline by Bristol-Myers Squibb Company, H1 2017
  • Pipeline by KAHR medical Ltd, H1 2017

This approval marks the third autoimmune disease indication for ORENCIA.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • 5. All the trials included are unique trials.

ADDISON' S DISEASE (PRIMARY OR CHRONIC ADRENAL INSUFFICIENCY) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, ADDISON' S DISEASE (PRIMARY OR CHRONIC ADRENAL INSUFFICIENCY) THERAPEUTICS CLINICAL TRIALS, GLOBAL, TOP COMPANIES BY PHASE, ADDISON' S

  • Autoimmune Disease
  • Pathology
  • Therapy
  • World
  • Product Initiative
  • ANTISENSE OLIGONUCLEOTIDE TO INHIBIT IL-1 BETA FOR EPIDERMOLYSIS BULLOSA - DRUG PROFILE
  • SPHERIUM BIOMED SL

The drug is approved for several autoimmune disorders and is being investigated for the management of heart disease.

  • Autoimmune Disease
  • Hospital
  • Therapy
  • United States
  • Product Initiative
  • NOV 13, 2017: BRISTOL-MYERS SQUIBB'S ORENCIA REJECTS FOR USE WITHIN NHS SCOTLAND
  • PIPELINE BY BRISTOL-MYERS SQUIBB CO, H2 2017

This approval marks the third autoimmune disease indication for ORENCIA.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • Pipeline by Bristol-Myers Squibb Co, H2 2017
  • Pipeline by KAHR medical Ltd, H2 2017

This approval marks the third autoimmune disease indication for ORENCIA.

  • Autoimmune Disease
  • Therapy
  • United States
  • Product Initiative
  • Bristol-Myers Squibb Company
  • BIOLOGICSMD INC
  • ALOPECIA - PIPELINE BY BRICKELL BIOTECH INC, H2 2017

Alopecia - Pipeline Review, H2 2017 Summary Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Alopecia - Pipeline Review, H2 2017, provides an overview of the Alopecia (Dermatology) pipeline landscape. Alopecia is the partial or complete loss of hair especially on the scalp either...

  • Autoimmune Disease
  • Hair Growth
  • Pharmaceutical
  • United States
  • Product Initiative